HIV vaccines: A brief overview

Scandinavian Journal of Immunology

Volumn 80, Issue 1, 2014, Pages 1-11

  Lema, D ^a   Garcia, A ^a   De Sanctis, J B ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VIRUS VACCINE; LIVE VACCINE;

CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; VIRUS PARTICLE;

AIDS VACCINES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD4-POSITIVE T-LYMPHOCYTES; DRUG DELIVERY SYSTEMS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84902654177     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12184     Document Type: Review

References (107)

1. Moodie Z, Janes H, Huang Y. New clinical trial designs for HIV vaccine evaluation. Curr Opin HIV AIDS 2013;8:436-41.
2. Rolland M, Gilbert P. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res Hum Retroviruses 2012;28:400-4.
3. Van Regenmortel MH. Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol 2012;3:194.
4. Corey L, Nabel GJ, Dieffenbach C et al. HIV-1 vaccines and adaptive trial designs. Sci Transl Med. 2011;3:79ps13.
5. McChesney MB, Miller CJ. New directions for HIV vaccine development from animal models. Curr Opin HIV AIDS 2013;8:376-81.
6. Barouch DH, Liu J, Li H et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482:89-93.
7. Genovese L, Nebuloni M, Alfano M. Cell-mediated immunity in elite controllers naturally controlling HIV viral load. Front Immunol 2013;4:86.
8. Jennes W, Sawadogo S, Koblavi-Dème S et al. Cellular human immunodeficiency virus (HIV)-protective factors: a comparison of HIV-exposed seronegative female sex workers and female blood donors in Abidjan, Côte d'Ivoire. J Infect Dis 2003;187:206-14.
9. Huang Y, Paxton WA, Wolinsky SM et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-3.
10. Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 2014;28:163-9.
11. Lindqvist M, van Lunzen J, Soghoian DZ et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest. 2012;122:3271-80.
12. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. Antibodies in HIV-1 vaccine development and therapy. Science 2013;341:1199-204.
13. Simek MD, Rida W, Priddy FH et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009;83:7337-48.
14. Murphy MK, Yue L, Pan R et al. Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 2013;9:e1003173.
15. Liao HX, Lynch R, Zhou T et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496:469-76.
16. Klein F, Diskin R, Scheid JF et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013;153:126-38.
17. Julien JP, Lee JH, Cupo A et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci USA 2013;110:4351-6.
18. Hessell AJ, Rakasz EG, Tehrani DM et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010;84:1302-13.
19. Huang J, Ofek G, Laub L et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012;491:406-12.
20. Guenaga J, Wyatt RT. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function. PLoS Pathog 2012;8:e1002806.
21. McCoy LE, Weiss RA. Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med 2013;210:209-23.
22. Munier CM, Andersen CR, Kelleher AD. HIV vaccines: progress to date. Drugs 2011;71:387-414.
23. Baum LL. Role of humoral immunity in host defense against HIV. Curr HIV/AIDS Rep 2010;7:11-8.
24. Overbaugh J, Morris L. The Antibody Response against HIV-1. Cold Spring Harb Perspect Med. 2012;2:a007039.
25. Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009;4:388-93.
26. Ampol S, Pattanapanyasat K, Sutthent R, Permpikul P, Kantakamalakul W. Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01_AE gp120. AIDS Res Hum Retroviruses 2012;28:1250-8.
27. Johnston MI, Fauci AS. HIV vaccine development-improving on natural immunity. N Engl J Med 2011;365:873-5.
28. Ackerman M, Alter G. Mapping the journey to an HIV vaccine. N Engl J Med 2013;369:389-91.
29. Moog C, Dereuddre-Bosquet N, Teillaud JL et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol 2014;7:46-56.
30. Jain S, Rosenthal KL. The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis. Mucosal Immunol 2011;4:539-53.
31. Hunt PW, Landay AL, Sinclair E et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS ONE 2011;6:e15924.
32. Ferrando-Martínez S, Casazza JP, Leal M et al. Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers. J Virol 2012;86:3667-74.
33. Streeck H, D'Souza MP, Littman DR, Crotty S. Harnessing CD4 T cell responses in HIV vaccine development. Nat Med 2013;19:143-9.
34. International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010;330:1551-7.
35. Koup RA, Douek DC. Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb Perspect Med 2011;1:a007252.
36. Ranasinghe SR, Kramer HB, Wright C et al. The antiviral efficacy of HIV-specific CD8 T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate. PLoS Pathog 2011;7:e1001341.
37. Tenzer S, Wee E, Burgevin A et al. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 2009;10:636-46.
38. Zagury D, Salaün JJ, Bernard J, Dechazal L, Goussard B, Lurhuma Z. Immunization against the human immunodeficiency virus in Zaire. Med Trop (Mars) 1988;48:417-23.
39. Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 2013;31:3502-18.
40. Excler JL, Tomaras GD, Russell ND. Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS 2013;8:420-30.
41. http://www.iavireport.org/Trials-Database/Pages/Results.aspx?searchid=8842fd6b-b1dd-4286-be8f-4b29b834bef1. September 16, 2013.
42. Beena V, Choudhary K, Rajeev R, Sivakumar R, Heera R, Padmakumar S. Human immunodeficiency virus vaccine an update. J Oral Maxillofac Pathol 2013;17:76-81.
43. Saunders KO, Rudicell RS, Nabel GJ. The design and evaluation of HIV-1 vaccines. AIDS 2012;26:1293-302.
44. De Gregorio E, Caproni E, Ulmer JB. Vaccine adjuvants: mode of action. Front Immunol 2013;4:214.
45. García A, De Sanctis JB. An overview of adjuvant formulations and delivery systems. APMIS 2013;122:257-67.
46. Stevceva L. Toll-like receptor agonists as adjuvants for HIV vaccines. Curr Med Chem 2011;18:5079-82.
47. Lind A, Brekke K, Sommerfelt M et al. Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms. Vaccine 2013;31:4611-8.
48. Butler NS, Nolz JC, Harty JT. Immunologic considerations for generating memory CD8 T cells through vaccination. Cell Microbiol 2011;13:925-33.
49. García F, Plana M, Climent N, León A, Gatell JM, Gallart T. Dendritic cell based vaccines for HIV infection: The way ahead. Hum Vaccin Immunother 2013;9:2445-52.
50. Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012;26:1261-8.
51. van der Sluis RM, Jeeninga RE, Berkhout B. Establishment and molecular mechanisms of HIV-1 latency in T cells. Curr Opin Virol 2013;3:700-6.
52. Santra S, Liao HX, Zhang R et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010;16:324-8.
53. Barouch DH, O'Brien KL, Simmons NL et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010;16:319-23.
54. Stephenson KE, Barouch DH. A global approach to HIV-1 vaccine development. Immunol Rev 2013;254:295-304.
55. Bontjer I, Melchers M, Tong T et al. Comparative immunogenicity of evolved V1V2-deleted HIV-1 envelope glycoprotein trimers. PLoS ONE 2013;8:e67484.
56. Haynes BF, Gilbert PB, McElrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:1275-86.
57. Martin G, Burke B, Thaï R et al. Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic. J Biol Chem 2011;286:21706-16.
58. Murphey-Corb M, Martin LN, Davison-Fairburn B et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989;246:1293-7.
59. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-41.
60. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999;73:8356-63.
61. Blower SM, Koelle K, Kirschner DE, Mills J. Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. Proc Natl Acad Sci USA 2001;98:3618-23.
62. Parks CL, Picker LJ, King CR. Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS 2013;8:401-10.
63. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191:654-65.
64. O'Connell RJ, Kim JH, Corey L, Michael NL. Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med 2012;2:a007351.
65. Pitisuttithum P, Gilbert P, Gurwith M et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194:1661-71.
66. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007;178:6596-603.
67. Cheong C, Choi JH, Vitale L et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 2010;116:3828-38.
68. Kumar D, Sharma D, Singh G, Singh M, Rathore MS. Lipoidal soft hybrid biocarriers of supramolecular construction for drug delivery. ISRN Pharm 2012;2012:474830.
69. Pastori C, Tudor D, Diomede L et al. Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. Virology 2012;431:1-11.
70. García-Arriaza J, Arnáez P, Gómez CE, Sorzano CO, Esteban M. Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. PLoS ONE. 2013;8:e66894.
71. Nascimento IP, Leite LC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res 2012;45:1102-11.
72. Price PJ, Torres-Domínguez LE, Brandmüller C, Sutter G, Lehmann MH. Modified Vaccinia virus Ankara: Innate immune activation and induction of cellular signalling. Vaccine 2013;31:4231-4.
73. http://clinicaltrials.gov/show/NCT01215149. March 31, 2014.
74. D'Souza MP, Frahm N. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS 2010;24:803-9.
75. Johnson JA, Barouch DH, Baden LR. Nonreplicating vectors in HIV vaccines. Curr Opin HIV AIDS 2013;8:411-9.
76. McElrath MJ, De Rosa SC, Moodie Z et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008;372:1894-905.
77. Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93.
78. O'Brien KL, Liu J, King SL et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009;15:873-5.
79. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010;5:357-61.
80. Masek-Hammerman K, Li H, Liu J et al. Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5. J Virol 2010;84:9810-6.
81. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20.
82. http://clinicaltrials.gov/show/NCT00223080. March 31, 2014.
83. de Souza MS, Ratto-Kim S, Chuenarom W et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012;188:5166-76.
84. Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccines 2010;9:997-1005.
85. Liu P, Yates NL, Shen X et al. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccines. J Virol 2013;87:7828-36.
86. Girard MP, Osmanov S, Assossou OM, Kieny MP. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 2011;29:6191-218.
87. Madhavi V, Kent SJ, Stratov I. HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality. Expert Rev Clin Immunol 2012;8:767-74.
88. Haynes BF, McElrath MJ. Progress in HIV-1 vaccine development. Curr Opin HIV AIDS 2013;8:326-32.
89. Coban C, Kobiyama K, Jounai N, Tozuka M, Ishii KJ. DNA vaccines: A simple DNA sensing matter? Hum Vaccin Immunother. 2013;9: 2216-21.
90. Kalams SA, Parker SD, Elizaga M et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013;208:818-29.
91. Zhou J, Cheung AK, Tan Z et al. PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. J Clin Invest 2013;123:2629-42.
92. Liu L, Qiu C, Huang Y, Xu J, Shao Y. Potent T cell responses induced by single DNA vaccine boosted with recombinant vaccinia vaccine. Virol Sin 2013;28:109-15.
93. Li M, Jiang Y, Xu C, Zhang Z, Sun X. Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant. Int J Nanomedicine 2013;8:1843-54.
94. Li J, Valentin A, Kulkarni V et al. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 2013;31:3747-55.
95. Hammer SM, Sobieszczyk ME, Janes H et al. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. N Engl J Med. 2013; 369: 2083-92.
96. Henriksen-Lacey M, Bramwell VW, Christensen D, Agger EM, Andersen P, Perrie Y. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release 2010;142:180-6.
97. Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immuneresponses to liposome associated antigens. Vaccine 2012;30:2256-72.
98. Bomsel M, Tudor D, Drillet AS et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011;34:269-80.
99. Brunner R, Jensen-Jarolim E, Pali-Schöll I. The ABC of clinical and experimental adjuvants-a brief overview. Immunol Lett 2010;128:29-35.
100. Launay O, Surenaud M, Desaint C et al. Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine 2013;31:4406-15.
101. Visciano ML, Tagliamonte M, Stewart-Jones G et al. Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate. J Transl Med 2013;11:165.
102. Horton RE, Vidarsson G. Antibodies and their receptors: different potential roles in mucosal defense. Front Immunol 2013;4:200.
103. Manrique M, Kozlowski PA, Cobo-Molinos A et al. Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes. J Virol 2013;87:4738-50.
104. Sircar P, Furr KL, Letvin NL. Systemic vaccination induces clonally diverse SIV-specific CD8+ T-cell populations in systemic and mucosal compartments. Mucosal Immunol 2013;6:93-103.
105. Ranasinghe C, Trivedi S, Stambas J, Jackson RJ. Unique IL-13Rα2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity. Mucosal Immunol 2013;6:1068-80.
106. Leroux-Roels G, Maes C, Clement F et al. Randomized phase I: safety, immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV-1 Gp41 P1 peptide on virosomes. PLoS ONE 2013;8:e55438.
107. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med 2012;63:95-111.